MET and neoplasm: Fortunately, current preclinical evidence in the listed studies suggested that tumor cells harboring MET fusions showed sensitivity to treatment with MET-TKIs, such as crizotinib, tepotinib, SGX523 and foretinib, indicating the basis for treatment methods for patients harboring MET fusions.